Puma Biotechnology (PBYI) Expected to Announce Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.24 per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Puma Biotechnology Price Performance

NASDAQ PBYI opened at $7.49 on Wednesday. Puma Biotechnology has a 1-year low of $2.58 and a 1-year high of $7.58. The company has a market capitalization of $377.42 million, a P/E ratio of 10.12 and a beta of 1.22. The business has a 50 day moving average price of $6.41 and a 200 day moving average price of $5.55.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Puma Biotechnology in a research note on Thursday, January 22nd. Wall Street Zen cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $7.00.

Insider Activity

In other news, insider Douglas M. Hunt sold 5,014 shares of Puma Biotechnology stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $5.88, for a total transaction of $29,482.32. Following the completion of the sale, the insider directly owned 155,907 shares in the company, valued at $916,733.16. The trade was a 3.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Alan H. Auerbach sold 18,012 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $5.88, for a total transaction of $105,910.56. Following the transaction, the chief executive officer directly owned 7,145,951 shares in the company, valued at $42,018,191.88. The trade was a 0.25% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 43,937 shares of company stock worth $257,513 over the last ninety days. 23.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Puma Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. increased its holdings in shares of Puma Biotechnology by 69.7% during the 4th quarter. Invesco Ltd. now owns 108,301 shares of the biopharmaceutical company’s stock worth $644,000 after buying an additional 44,484 shares during the last quarter. Empowered Funds LLC grew its position in Puma Biotechnology by 55.7% during the fourth quarter. Empowered Funds LLC now owns 186,185 shares of the biopharmaceutical company’s stock valued at $1,108,000 after acquiring an additional 66,624 shares during the period. Stokes Family Office LLC acquired a new stake in Puma Biotechnology during the fourth quarter worth about $167,000. Verdad Advisers LP acquired a new stake in Puma Biotechnology during the fourth quarter worth about $330,000. Finally, Man Group plc purchased a new position in shares of Puma Biotechnology in the 4th quarter worth about $282,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.